ReviewCold Spring Harbor perspectives in medicine2016
β-Lactams and β-Lactamase Inhibitors: An Overview.
Review in Cold Spring Harbor perspectives in medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 651 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
651 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,216 citations in OpenAlex.
- β-lactam infusion strategies in critical illness: is continuous superior to extended infusion? A systematic review and network meta-analysis.Frontiers in epidemiology · 2026Pooled it
- Systemic Antibiotics in the Surgical Treatment of Peri-Implantitis: Impact on the Salivary Microbiome.Journal of clinical periodontology · 2026Trial
- Dietary and nutritional strategies for reducing disease risk associated with antibiotic-induced dysbiosis.Gut microbes · 2026Review
- Review
- Review
- Quantifying antibiotic susceptibility and inoculum effects using transient dynamics of Pseudomonas aeruginosa.PLoS computational biology · 2026Article
- Novel Bacterial Topoisomerase Inhibitors: A New Front in an Old War.Journal of molecular biology · 2026Review
- Article
- Effect of combined piperine and amoxicillin as an efflux pump inhibitor for metal-tolerant and antibiotic - resistant E. coli in broilers.Veterinary research communications · 2026Article
- β-Lactam antibiotics trigger mouse TLR2/4- and human TLR2/5-dependent Jarisch-Herxheimer reaction in leptospirosis.bioRxiv : the preprint server for biology · 2026Article
- Chelate-conjugated β-lactams resensitize metallo-β-lactamase IMP-1-producing gram-negative bacteria against carbapenem antibiotics.Microbiology spectrum · 2026Article
- UropathogenicAntibiotics (Basel, Switzerland) · 2026Review
- Orbital Tuning of the β-Lactam Warhead: Intrinsic n → π* Preactivation in Cephalosporins.The journal of physical chemistry letters · 2026Article
- Restoring Meropenem Activity Against VIM-1-Producing Klebsiella pneumoniae Through Zinc-Binding Ligands.Chembiochem : a European journal of chemical biology · 2026Article
- Bacterial biosynthetic superclusters: emerging drivers of synergistic natural products against antimicrobial resistance.Essays in biochemistry · 2026Review
- Proteome Remodeling of a Carbapenem-Resistant Escherichia coli Strain upon Meropenem Exposure.Journal of proteome research · 2026Article
- Plant-Derived Compounds as Antibiotic Adjuvants Against Drug-Resistant ESKAPE Pathogens: Mechanisms of Action, Synergistic Strategies, and Translational Challenges.Antibiotics (Basel, Switzerland) · 2026Review
- Tail-specific protease (Tsp)-mediated envelope remodeling and beta-lactam tolerance inMicrobiology spectrum · 2026Article
- Synergistic mode of action of a ceftazidime-hexa-arginine conjugate with resistance-overcoming properties.Microbiology spectrum · 2026Article
- Enhanced antibacterial activity of amoxicillin combination with a Cu-Fe sulfide mineral against antimicrobial-resistant bacteria.Folia microbiologica · 2026Article
591 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of β-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options. This work provides a comprehensive overview of β-lactam antibiotics that are currently in use, as well as a look ahead to several new compounds that are in the development pipeline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.